FMR LLC, a prominent institutional investor with a stake exceeding 10% in Beam Therapeutics Inc., has executed a significant reduction in its ownership position. The divestment involves the sale of shares valued at approximately $10.04 million. These transactions were completed over a two-day period in late June, specifically on June 25 and June 26, 2026. The timing of this sale is particularly notable given that Beam Therapeutics stock was trading near its 52-week high of $36.88 at the time. The stock has experienced a substantial 107% gain over the past year, which may contextualize the strategic reduction by the major shareholder. Market analysis from InvestingPro indicates that BEAM currently appears overvalued based on established fair value metrics.
Regulatory filings provide a detailed breakdown of the transactions. On June 25, 2026, FMR LLC sold 33,372 shares of common stock. This specific block was sold indirectly through F-Prime Capital Partners Healthcare Fund V LP. The weighted average price for these shares was $35.12, with individual trade executions ranging between $35.00 and $35.39. The following day, on June 26, 2026, the entity sold an additional 251,488 shares. This second transaction also utilized F-Prime Capital Partners Healthcare Fund V LP as the indirect vehicle. The weighted average price for this block was $35.26 per share, with individual trade prices spanning from $35.00 to $35.88. Following these sales, F-Prime Capital Partners Healthcare Fund V LP retained a holding of 854,583 shares of Beam Therapeutics common stock.
Beyond the primary divestment, FMR LLC disclosed other indirect holdings in the company. These include 14 shares held by FMR Capital, Inc., and 841,231 shares held by various other persons and entities that are subject to reporting requirements under FMR LLC. The cumulative data from these filings highlights the scale of institutional management involved in Beam Therapeutics equity.
In parallel with the shareholder activity, Beam Therapeutics has reported significant developments in its clinical pipeline. The U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug application for BEAM-304. This treatment is designed to target phenylketonuria. The company is advancing BEAM-304 using a distinct development strategy that incorporates multiple mutation-specific base editors within a single clinical program. Furthermore, Beam Therapeutics presented clinical data from its BEAM-302 Phase 1/2 trial for alpha-1 antitrypsin deficiency at the American Thoracic Society International Conference. The presentation detailed safety and efficacy results derived from 29 patients. The data highlighted durable increases in total and functional AAT, alongside a reduction in human neutrophil elastase activity.
Market analysts have also weighed in on the company's progress. H.C. Wainwright has reiterated its Buy rating on Beam Therapeutics, maintaining a price target of $80.00. The firm cited the pivotal readiness of BEAM-302 and the preparation for the risto-cel Biologics License Application (BLA) as primary factors supporting this stance. H.C. Wainwright noted the company's advancement in both its liver-targeted genetic disease and hematology franchises. Additionally, the firm identified 60 mg as the optimal biological dose for BEAM-302. Beam Therapeutics further announced plans to present updated biomarker data from its BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel in sickle cell disease at the upcoming European Hematology Association Congress. This presentation will focus on analyses regarding red blood cell health and the correlation between fetal hemoglobin and clinical outcomes.